 |
|
Congenital Myasthenic Syndrome With Episodic Apnea in Patients Homozygous for a CHAT Missense Mutation
Simone Kraner;
Iris Laufenberg;
Hans M. Straßburg, MD;
Joern P. Sieb, MD;
Ortrud K. Steinlein, MD
Arch Neurol. 2003;60:761-763.
ABSTRACT
Background The syndrome of congenital myasthenia with episodic apnea (CMS-EA) was previously found to be due to mutations in the choline acetyltransferase gene (CHAT).
Objective To identify the mutations underlying CMS-EA in a Turkish multiplex family.
Design Direct sequencing of the CHAT gene.
Patients A consanguineous Turkish family with 2 siblings affected by muscular weakness and episodic respiratory distress.
Results The sequencing of CHAT coding exons identified a previously unknown missense mutation that affected a highly conserved amino acid residue (I336T). The mutation was absent in 164 control chromosomes.
Conclusions The high degree of conservation in different species strongly suggests that I336T is a functionally important amino acid residue. The absence of I336T from a large control sample further supports the pathogenic role of I336T in CMS-EA. This is the second report of CHAT mutations causing presynaptic CMS.
INTRODUCTION
IMPAIRMENT OF neuromuscular transmission can either be acquired or inherited. Congenital myasthenic syndromes (CMS) are due to gene mutations in proteins located in the presynaptic, synaptic, or postsynaptic part of the neuromuscular junction.1-4 Presynaptic defects are caused by mutations in the gene coding for the enzyme choline acetyltransferase (ChAT), while synaptic CMS was found to be associated with end plate acetylcholinesterase deficiency due to COLQ (collagen-like tail subunit of asymmetric acetylcholinesterase) mutations. In patients with postsynaptic CMS, mutations have been found in all 4 genes coding for subunits of the adult-type muscular nicotinic acetylcholine (ACh) receptor as well as in the gene coding for the ACh receptor–associated protein rapsyn.1-4
Mutations in the CHAT gene have recently been identified as a cause of the frequently fatal congenital myasthenia with episodic apnea syndrome (CMS-EA), previously named familial infantile myasthenia.5 Congenital myasthenia with episodic apnea usually manifests at birth or in the neonatal period with hypotonia, ptosis, dysphagia, and respiratory insufficiency with apnea. If the patient survives this initial phase, the condition improves, but recurrent crises, such as infections, fever, vomiting, or overexertion, may result in sudden death or anoxic brain damage. Acetylcholinesterase inhibitors are effective in preventing or moderating these life-threatening crises. In CMS-EA, end plates show no morphologic abnormality. In vitro studies on intercostal muscle specimens have elucidated the electrophysiologic basis of this disorder of neuromuscular transmission. Prolonged stimulation of muscle bundles at 10 Hz results in an abnormal decrease of the amplitude of the miniature end plate potentials (MEPPs).6 This decrease of MEPP amplitude on prolonged stimulation suggests a progressive decrease in the acetylcholine content of the presynaptic vesicles. The recently described CHAT mutations5 reduce or abolish the synthesis of acetylcholine from acetyl coenzyme A and choline at the cholinergic synapses. We have screened the CHAT gene in a multiplex CMS-EA family of Turkish origin and have identified a previously unknown missense mutation affecting a highly conserved amino acid residue.
METHODS
CMS-EA FAMILY AND CONTROLS
The pedigree of the CMS-EA family is shown in Figure 1. The ethical committee of the University Hospital Bonn (Bonn, Germany) approved the study, and informed consent was obtained from the participating individuals or their respective parents. The patients are 2 siblings from a consanguineous Turkish family (Figure 1). The parents did not report any abnormality during the pregnancy and birth of both children. The more severely affected sibling, a boy, had 3 episodes of acute-onset respiratory distress with cyanosis during infancy. In both siblings, motor milestones were delayed. They had already shown increased fatigability as toddlers. They were never able to keep up physically with their peers. Their exertion tolerance decreased continuously during childhood. At the age of 7 years, the boy had to stop walking approximately every 10 m for a brief rest. He experienced repeated infections that resulted in rapid decline of the remaining muscle force, requiring ventilatory support. Although he improved significantly while taking acetylcholinesterase inhibitors during these exacerbations, recovery was delayed, and he was hospitalized for weeks at a time on many occasions. On examination, the siblings showed ptosis pronounced by sustained upward gaze but no ophthalmoparesis. Limb and girdle muscles fatigued easily. Additionally, the sister suffered from bilateral developmental hip dysplasia. Chronic aggressive hepatitis B, probably due to co-natal infection, was present in the brother. Pronounced decremental electromyographic (EMG) responses at 3-Hz stimulation were detected only when the tested muscles were weak due to exercise. Low-frequency stimulation failed to result in abnormal decremental responses after rest. The EMG decrements, when present, were corrected by edrophonium chloride, probably because this reversible cholinesterase inhibitor increases the amount of ACh available at the neuromuscular junction. Repeated tests for the presence of anti-ACh receptor antibodies were negative. The parents did not give consent for muscle biopsies. The control sample consisted of DNA from 82 unrelated healthy individuals of European descent.
|
|
|
|
Figure 1. Pedigree of the Turkish family with congenital myasthenia with episodic apnea. A star marks the index patient. A double line indicates the consanguineous marriage. The genotypes of individuals available for analysis are given below the symbols, and examples of the sequencing results (reverse strand) are given for both I336T heterozygotes (upper part) and homozygotes. An arrow marks the mutation found in the present study.
|
|
|
MUTATION SCREENING
Polymerase chain reaction (PCR) was performed using primer sets that amplified CHAT coding exons 2 to 14 and their adjacent exon-intron boundaries. Polymerase chain reaction was carried out in a total volume of 25 mL in a PTC (Peltier thermal cycler) 200 (MJ Research, Waltham, Mass), containing 50 ng of genomic DNA, 5 pmol of each forward and reverse primer, 200 mM of each deoxynucleotide triphosphated NTP, 1.5 mM of magnesium chloride, 50 mM of potassium chloride, 20 mM of Tris-hydrochloride (pH 8.3), and 0.1 U of Taq-DNA polymerase. The PCR parameters were as follows: denaturation at 95°C for 5 minutes followed by 33 cycles at 95°C for 30 seconds, annealing at 66° to 72°C for 30 seconds, extension times at 72°C, varying between 30 seconds and 80 seconds, followed by a final extension step of 5 minutes at 72°C. The PCR products were directly sequenced on an ABI 377 sequencer (Applied Biosystems, Foster City, Calif).
RESTRICTION DIGEST
The I336T mutation creates a site for the restriction endonuclease, Tsp4CI, allowing a rapid screening of controls. Exon 7 was amplified using primers n1743 (5'-ACGGGCCACCCAACAAGTGACA-3') and n1744 (5'-GAAAGCCAATGGGCACGAGCAT-3'). The amplified fragment contained 3 additional Tsp4CI restriction sites serving as internal controls. Five milliliters of the resulting 110–base pair (bp) PCR product were digested with Tsp4CI and separated on a 3% agarose gel. The following bands were observed: wild-type allele, 44 bp + 68 bp + 170 bp; mutant allele, 44 bp + 68 bp + 75 bp + 95 bp.
RESULTS
Polymerase chain reaction amplification and subsequent direct sequencing of CHAT exons from the DNA of the index patient revealed a homozygous thymine to cytosine nucleotide exchange within exon 7, leading to the substitution of isoleucine by threonine in amino acid position 336 (I336T; nucleotide numbering referring to the complementary DNA sequence of CHAT isoform M, accession number NM020549). Sequencing of additional family members showed that the affected sister was homozygous for the amino acid exchange I336T, while both healthy parents were heterozygous for the mutation. The I336T mutation was not found in 164 chromosomes from healthy controls.
COMMENT
Choline acetyltransferase catalyses the synthesis of the neurotransmitter acetylcholine from acetyl coenzyme A and choline in central and peripheral neurons. A single gene with different promoter regions, which can produce several transcripts, encodes the enzyme. In humans, the M-type RNA has the capability to generate both large and small forms of ChAT proteins, while R- and N-type RNA generate only the small form.7 Deficiency of ChAT protein expression has been reported in different neurodegenerative conditions, such as Alzheimer disease,8 Parkinson disease,9 and amyotrophic lateral sclerosis.10 Abnormalities of ChAT activity have also been described in schizophrenia11 and sudden infant death syndrome.12 In most of these diseases, the reason for the observed loss of ChAT activity is either unknown or suspected to be secondary to a loss of cholinergic neurons. So far, no mutations within the CHAT gene or its promoter have been identified in disorders of the central nervous system. The only CHAT mutations identified to date were found in patients with CMS-EA, a disorder originating from peripheral motor neurons.5
The ChAT protein belongs to the family of eukaryotic acetyltransferases, which also includes carnitine acetyltransferases, peroxisomal carnitine octanoyltransferases, and mitochondrial carnitine palmitoyltransferases. Comparison of acetyltransferase sequences from different species showed that the amino acid residue I336 is highly conserved and can be found even in species as evolutionary diverse as Mycoplasma pulmonis or Neurospora crassa (Figure 2). Although sequence pattern prediction programs do not relate the mutated I336 to a known protein motif, the high degree of conservation strongly suggests a functionally important role for this amino acid residue. That I336T is a mutation and not a functionally neutral polymorphism was further supported by its absence in the large control sample and by its homozygous presence in the 2 patients. Previously reported functional experiments have shown that point mutations in different positions within the ChAT protein decrease the catalytic activity of the enzyme.5 This observation could explain the recurrently occurring crises seen in CMS-EA patients; in situations leading to physical or emotional stress, the impaired ChAT protein is probably not able to meet the increased demand for acetylcholine at the neuromuscular junction.
|
|
|
|
Figure 2. Evolutionary conservation of amino acid residue I336 within the family of eukaryotic acetyltransferases. Only parts of the protein sequences are shown. A box marks the position of I336.
|
|
|
Only 2 of the 10 ChAT mutations analyzed so far caused nonfunctionality of the ChAT protein. Neither of the patients was homozygous for any of these null mutations, but carried an enzymatically active ChAT mutation on the second allele. Given the important function of ChAT in peripheral and central cholinergic neurons, it is not surprising that patients with CMS-EA still have some residual ChAT function. As shown in knockout mice, a complete failure of ChAT enzymatic activity causes a lethal phenotype.13 It is therefore most likely that the I366T mutation reported here reduces but not abolishes ChAT function. The residual ChAT activity is probably the reason why, despite the important function of ChAT in the brain, CMS-EA patients have no signs of central cholinergic dysfunction.
AUTHOR INFORMATION
| |
Corresponding author: Ortrud K. Steinlein, MD, Institute of Human Genetics, University Hospital, Wilhelmstr 31, D-53111 Bonn, Germany (e-mail: ortrud.steinlein{at}ukb.uni-bonn.de).
Accepted for publication July 9, 2002.
Author contributions: Study concept and design (Drs Sieb and Steinlein); acquisition of data (Ms Laufenberg and Drs Straßburg and Steinlein); analysis and interpretation of data (Mss Kraner and Laufenberg and Drs Sieb and Steinlein); drafting of the manuscript (Mss Kraner and Laufenberg and Drs Sieb and Steinlein); critical revision of the manuscript for important intellectual content (Drs Straßburg and Steinlein); statistical expertise (Dr Steinlein); obtained funding (Drs Sieb and Steinlein); administrative, technical, and material support (Mss Kraner and Laufenberg and Dr Straßburg); study supervision (Drs Sieb and Steinlein).
This study was supported by grant STE 769/3-2 from the Deutsche Forschungsgemeinschaft, Germany (Drs Sieb and Steinlein).
From the Institute of Human Genetics, University Hospital, Rheinische-Friedrich-Wilhelms University of Bonn, Bonn (Mss Kraner and Laufenberg, and Dr Steinlein); Department of Pediatrics, Bavarian-Ludwig-Maximilians University of Würzburg, Würzburg (Dr Straßburg); and the Department of Neurology, Max Planck Institute of Psychiatry, Munich (Dr Sieb), Germany.
REFERENCES
1. Engel AG, Ohno K. Congenital myasthenic syndromes. Adv Neurol. 2002;88:203-215.
PUBMED
2. Ohno K, Engel AG. Congenital myasthenic syndromes: genetic defects of the neuromuscular junction. Curr Neurol Neurosci Rep. 2002;2:78-88.
PUBMED
3. Sieb JP, Kraner S, Steinlein OK. Congenial myasthenic syndromes. Semin Pediatr Neurol. 2002;9:108-119.
FULL TEXT
| PUBMED
4. Ohno K, Engel AG, Shen XM, et al. Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am J Hum Genet. 2002;70:875-885.
FULL TEXT
|
ISI
| PUBMED
5. Ohno K, Tsujino A, Brengman JM, et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A. 2001;98:2017-2022.
FREE FULL TEXT
6. Mora M, Lambert EH, Engel AG. Synaptic vesicle abnormality in familial infantile myasthenia. Neurology. 1987;37:206-214.
FREE FULL TEXT
7. Eiden LE. The cholinergic gene locus. J Neurochem. 1998;70:2227-2240.
ISI
| PUBMED
8. Baskin DS, Browning JL, Pirozzolo FJ, Korporaal S, Baskin JA, Appel SH. Brain choline acetyltransferase and mental function in Alzheimer disease. Arch Neurol. 1999;56:1121-1123.
FREE FULL TEXT
9. Mattila PM, Roytta M, Lonnberg P, Marjamaki P, Helenius H, Rinne JO. Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol. 2001;102:160-166.
PUBMED
10. Berger ML, Veitl M, Malessa S, Sluga E, Hornykiewicz O. Cholinergic markers in ALS spinal cord. J Neurol Sci. 1992;108:114-117
FULL TEXT
|
ISI
| PUBMED
11. Karson CN, Mrak RE, Husain MM, Griffin WS. Decreased mesopontine choline acetyltransferase levels in schizophrenia: correlations with cognitive functions. Mol Chem Neuropathol. 1996;29:181-191.
ISI
| PUBMED
12. Mallard C, Tolcos M, Leditschke J, Campbell P, Rees S. Reduction in choline acetyltransferase immunoreactivity but not muscarinic-m2 receptor immunoreactivity in the brainstem of SIDS infants. J Neuropathol Exp Neurol. 1999;58:255-264.
ISI
| PUBMED
13. Brandon EP, Lin W, D'Amour KA, et al. Developmental defects in choline acetyltransferase knockout mice. Soc Neurosci Abs. 2000;26:1089.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Identification of a Mutation in the CHAT Gene of Old Danish Pointing Dogs Affected with Congenital Myasthenic Syndrome
Proschowsky et al.
J Hered 2007;0:esm026v2.
ABSTRACT
| FULL TEXT
|
